Phase 1 N=38 Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults
Middle East Respiratory Syndrome Coronavirus
Primary: Number of Participants Having Adverse Events — 1; 2; 2; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=92 Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
Lymphoma
Primary: Overall Response Rate (ORR) as Determined by IRRC — 4.3 Percentage of participants
Phase 3 N=510 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
Cystic Fibrosis
Primary: Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24 — -0.6; 3.4 Percentage of predicted FEV1…
N/A N=160 Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management
Postoperative Pain
Primary: Opioid Consumption in the 0-48 Hour Study Periods. — 10; 5; 10; 5 milligram morphine equivalents (MMEQ)
Phase 2 N=24 A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
Jansky-Bielschowsky Disease · Batten Disease · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Primary: Motor-Language (ML) Scale Score During 300 mg Dosing Period — 3.5; 3.1; -0.4 units on a scale — p=0.0002
N/A N=200 Post-Operative Delirium in Elderly Surgical Patients
Hip Fractures · Delirium
Primary: Number of Participants With the Presence of Delirium as Assessed by the Confusion Assessment Method — 39; 34 Participants
N/A N=33 Low Intensity Ultrasound Therapy for Upper Back Pain Relief
Muscle Spasm
Primary: Pain on the Numeric Rating Scale (NRS) — 5.60; 5.44; 3.54; 4.58 units on a scale
N/A N=137 Lifestyle Modification and Lorcaserin for Weight Loss Maintenance
Obesity
Primary: Change in Weight (kg) — 2.0; 2.5 kg
Phase 3 N=2,014 A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia
Primary: Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension — 3; 6; 1; 0…
Phase 3 N=634 A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol — 2.6 g/dL — p=<0.0001
Phase 3 N=812 A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Participants Who Achieved A ≥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5 — 252; 5; 386; 7 Participants — p=<0.0001
Phase 2 N=22 Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
Pompe Disease
Primary: Number of Participants With Adverse Events — 3; 3; 15 Participants
N/A N=10 Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H
End Stage Renal Disease
Primary: BPA Level Following 2 Months of Dialysis — 9.76; 1.55 ng/mL — p=0.05
Phase 3 N=567 Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm — 88.6; 92.4 percentage of participants — p=0.15
Phase 2 N=20 Nuedexta in Treatment-Resistant Major Depression
Major Depressive Disorder · Treatment Resistant
Primary: Montgomery-Asberg Depression Rating Scale — -13.0 change in units on a scale